Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
This is a immune-response modifier, used in the local treatment of genital and perianal warts, cutaneous basal cell tumors and actinic keratosis.
Administered topically, once a day or every two days for several weeks, according to pathology.
Since the last update we have not found any published data on its excretion in breastmilk.
The cutaneous absorption to the patient's blood is extremely low: 0.6% with a Cmax of 0.32 to 1.6 ng/mL (EMA 2016, Wu 2012, Kulp 2010, Harrison 2004, FDA 2004), which makes it very unlikely that there is transfer in significant amounts to breastmilk.
It is used in the topical treatment of infantile hemangiomas from a month of life (Satterfield 2019, Craiglow 2013, Ho 2007).
As with any product applied to the skin, it is prudent to avoid its use in areas near the breast and nipple so that there is no risk of swallowing by the infant.